What is the current market size and future outlook for the sorafenib market?
The sorafenib market size has grown steadily in recent years. It will grow from $1.24 billion in 2024 to $1.3 billion in 2025 at a compound annual growth rate (CAGR) of 4.4%. The growth in the historic period can be attributed to favorable government policies and reimbursement programs, increasing approvals for new drugs, increasing apoptosis in cancer cells, rising incidence of target cancers, and growing research studies on sorafenib.
The sorafenib market size is expected to see steady growth in the next few years. It will grow to $1.53 billion in 2029 at a compound annual growth rate (CAGR) of 4.2%. The growth in the forecast period can be attributed to the increasing incidence of thyroid cancer, increasing incidence of cancer, increase in prevalence of chronic diseases, increasing focus on precision medicine, and rising incidence of liver and renal cancers. Major trends in the forecast period include advancements in early diagnosis and treatment, innovations in alternative therapies, advanced hepatocellular carcinoma (HCC), technological innovations in drug delivery, and advanced renal cell carcinoma.
Get Your Free Sample of The Global Sorafenib Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19199&type=smp
How has the sorafenib market evolved, and what factors have shaped its growth?
The increasing prevalence of cancer is expected to propel the growth of the sorafenib market going forward. Cancer is a term used to describe a group of disorders in which abnormal cells grow and divide uncontrollably, with the potential to invade and harm healthy bodily tissue. The increasing prevalence of cancer is due to a combination of factors, including aging populations, lifestyle choices, environmental exposures, and advances in diagnostic technology that lead to more cases being detected. Sorafenib, a multi-kinase inhibitor, plays a crucial role in cancer treatment by targeting key signaling pathways involved in tumor growth and angiogenesis, providing an effective therapeutic option for patients with advanced renal cell carcinoma and hepatocellular carcinoma. For instance, in January 2023, according to the National Center for Biotechnology Information, a US-based intergovernmental organization, around 1,958,310 new cancer cases and 609,820 cancer deaths occurred in 2023. Therefore, the increasing prevalence of cancer is driving the growth of the sorafenib market.
What are the major segments of the sorafenib market?
The sorafenibmarket covered in this report is segmented –
1) By Product: Patented Drugs, Generic Drugs
2) By Distribution Channel: Hospital Pharmacies, Drug Store And Retail Pharmacies, Online Pharmacies
3) By Application: Kidney Cancer, Liver Cancer, Thyroid Cancer
Subsegments:
1) By Patented Drugs: Nexavar
2) By Generic Drugs: Generic Sorafenib Tosylate, Other Generic Variants
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/sorafenib-global-market-report
Which companies dominate the sorafenib market?
Major companies operating in the sorafenib market are Pfizer Inc., Bayer AG, AstraZeneca PLC, Novartis AG, Bristol Myers Squibb , Mylan N.V., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Amgen Inc., Cipla Limited, Hikma Pharmaceuticals PLC, Dr. Reddy’s Laboratories Ltd., Exelixis Inc., Natco Pharma, Beacon Pharmaceuticals Ltd., Hetero Healthcare Ltd., Aprazer Healthcare Private Limited, Wellona Pharma, Anant Pharmaceuticals Pvt. Ltd., Intelicure Lifescience
How will evolving trends contribute to the growth of the sorafenib market?
Major companies operating in the sorafenib market are focusing on developing innovative products, such as sorafenib tablets in affordable generic medicines, to enhance efficacy and patient compliance while addressing specific needs in cancer treatment. Affordable generic medicines are medications that offer the same therapeutic benefits as brand-name drugs but at significantly lower prices. These medicines help reduce healthcare costs while maintaining the same clinical efficacy as their brand-name versions. For instance, in June 2022, Dr. Reddy’s Laboratories, an India-based company that manufactures pharmaceuticals, launched Sorafenib tablets, a generic product used in the treatment of various cancers, in the US market approved by the US Food and Drug Administration (USFDA). This product is a generic version of Bayer’s Nexavar, used for treating various cancers, including liver, kidney, and thyroid. The Sorafenib tablets are available in 200 mg dosages and are packaged in bottles containing 120 tablets.
What are the key regional dynamics of the sorafenib market, and which region leads in market share?
North America was the largest region in the sorafenib market in 2024. The regions covered in the sorafenib market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Sorafenib Market Report 2025 Offer?
The sorafenib market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Sorafenib is a medication used primarily in the treatment of certain types of cancer. It is classified as a targeted therapy drug and works by inhibiting specific enzymes and proteins involved in cancer cell growth and tumor blood vessel formation.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19199
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
